HEALTH PROFESSIONAL · SOURCE READING

Allogeneic Bone Marrow Transplant (BMT) or Stem Cell Transplant (SCT)

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for CML

Allogeneic BMT or SCT has also been used with curative intent.[6] Long-term data beyond 10 years of therapy are available, and most long-term survivors show no evidence of the BCR::ABL1 translocation by any available test (e.g., cytogenetics, reverse transcription–polymerase chain reaction, or fluorescence in situ hybridization). Some patients, however, are not eligible for this approach because of age, comorbid conditions, or lack of a suitable donor. In addition, substantial morbidity and mortality result from allogeneic BMT or SCT; a 5% to 10% treatment-related mortality can be expected, depending on whether a donor is related and the presence of mismatched antigens.[6]

Source links and citations

Evidence (allogeneic SCT vs. drug treatment):

In a prospective trial of 427 transplant-eligible, previously untreated patients, 166 patients were allocated to allogeneic SCT, and 261 patients were allocated to drug treatment (mostly imatinib).[6][Level of evidence C1] Similar outcomes were seen in patients who underwent allogeneic SCT because of TKI intolerance or nonadherence.[7]

Source links and citations

No difference in 10-year overall survival was reported between the treatment groups.

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice